Hodnota metriky Inštitucionálne vlastníctvo spoločnosti Apellis Pharmaceuticals Inc je 90.92%
Inštitucionálne vlastníctvo (Institutional Ownership) je množstvo akcií spoločnosti vlastených podielovými alebo penzijnými fondami, poisťovňami, investičnými firmami, a ďalšími entitami, ktoré spravujú peňažné prostriedky iných.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.